New estrogen guidelines: 2 experts give opposing views

Drs. Love and Notelovitz articulate different positions and offer practice recommendations.

Professor of surgery David Geffen School of Medicine University of California,  Los Angeles

Consultant
Adult women’s health and medicine Boca Raton, Fla,  Washington, DC

The decision by the US Food and Drug Administration (FDA) to put warning labels on all estrogen and estrogen-progestin products prescribed for postmenopausal women is startling—especially when you consider that barely a year ago, estrogen was viewed as a remedy or preventive for all kinds of ills.

This reversal in the official status of estrogen has created shock waves among Ob/Gyns still struggling to answer patients’ questions and counsel them appropriately.